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PCONGENITAL HEART DISEASE
Changing Mortality in Congenital Heart Disease
Paul Khairy, MD, PHD,* Raluca Ionescu-Ittu, MSC,†§ Andrew S. Mackie, MD, SM,†
Michal Abrahamowicz, PHD,§ Louise Pilote, MD, MPH, PHD,‡§ Ariane J. Marelli, MD†
Montreal, Quebec, Canada
Objectives This study sought to characterize temporal trends in all-cause mortality in patients with congenital heart disease
(CHD).
Background Historically, most deaths in patients with CHD occurred in early childhood. Notable advances have since been
achieved that may impact on mortality trends.
Methods We conducted a population-based cohort study of patients with CHD in Quebec, Canada, from July 1987 to June
2005. A total of 8,561 deaths occurred in 71,686 patients with CHD followed for 982,363 patient-years.
Results The proportion of infant and childhood deaths markedly declined from 1987 to 2005, with a reduction in mortal-
ity that exceeded that of the general population. Distribution of age at death transitioned from a bimodal to uni-
modal, albeit skewed, pattern, more closely approximating the general population. Overall, mortality decreased
by 31% (mortality rate ratio: 0.69, 95% confidence interval [CI]: 0.61 to 0.79) in the last (2002 to 2005) relative
to the first (1987 to 1990) period of observation. Mortality rates decreased in all age groups below 65 years,
with the largest reduction in infants (mortality rate ratio: 0.23, 95% CI: 0.12 to 0.47). In adults 18 to 64 years,
the mortality reduction (mortality rate ratio: 0.84, 95% CI: 0.73 to 0.97) paralleled the general population. Gains
in survival were mostly driven by reduced mortality in severe forms of CHD, particularly in children (mortality rate
ratio: 0.33, 95% CI: 0.19 to 0.60), and were consistent across most subtypes.
Conclusions Deaths in CHD have shifted away from infants and towards adults, with a steady increase in age at death and
decreasing mortality. (J Am Coll Cardiol 2010;56:1149–57) © 2010 by the American College of Cardiology
Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.03.085r
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rongenital heart disease (CHD) is the most common form
f major birth defects, affecting over 1% of newborns (1).
istorically, most patients with CHD died in early child-
ood. However, the past 4 decades have witnessed extraor-
inary advances in this field (2–7). Indeed, population
revalence studies indicate that the number of adults now
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010, accepted March 2, 2010.ivals the number of children with severe defects (1).
hanging patterns of death in this growing population must
e investigated to adequately plan allocation of health care
esources. We established a unique population-based database
hat includes over 70,000 patients with CHD followed for
early 1 million patient-years and that captures all deaths from
987 to 2005. Our objective was to characterize temporal
rends in all-cause mortality in patients with CHD.
ethods
ata sources and collection. Quebec is the second most-
opulated province in Canada, with over 7.6 million inhab-
tants. A unique Medicare number is assigned to every
ndividual, and all diagnoses and health services provided
re systematically recorded over a lifespan (1). The physi-
ian’s services and claims database contains demographic
ata and records on all patients who contacted the health
are system, as inpatients or outpatients, and includes
iagnostic and therapeutic procedures performed since
982. Diagnostic codes adhere to the International Classi-
cation of Disease-Ninth Revision (ICD-9). As physician
emuneration is based on these claims, there is a strong
ncentive to divulge all professional activities. The hospital
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Changing Mortality in Congenital Heart Disease September 28, 2010:1149–57discharge summary database con-
tains records on all hospital admis-
sions and captures demographic
data, diagnostic codes, and thera-
peutic procedures. All diagnoses
are linked with specialty-specific
provider codes.
Data on all patients with a
diagnosis of CHD between Jan-
uary 1, 1983, and June 30, 2005,
who were alive on or born after
uly 1, 1987, were obtained from the Quebec Health
nsurance Board. To protect patient confidentiality, infor-
ation was transmitted with encrypted identifiers. Using
he same encrypted numbers, the Quebec Ministry of
ealth provided additional hospitalization discharge data.
hese source databases were linked for each individual,
hereby generating a comprehensive record of health care
overage for patients with CHD. The study was approved
y the McGill University Health Center ethics board and
he Quebec government agency responsible for privacy of
ccess to information.
tudy population. A hierarchical categorization scheme,
ummarized in Table 1, was used to classify patients with
HD (1). We identified all patients with at least 1 diag-
ostic code for CHD and/or surgical procedure specific to
hese codes who came into contact with the health care
ystem. The 24 ICD-9 diagnostic codes and corresponding
urgical codes were grouped into 5 categories of decreasing
pecificity (Table 1) and cross-referenced between source
dministrative databases.
Using provider codes, physicians reporting diagnostic
odes or procedures were classified as cardiovascular special-
st (pediatric, medical, or surgical), primary care physician
general or family physician, pediatrician, or internist),
chocardiographer, or other (1). When more than 1 ICD-9
ode was recorded, the most frequent diagnosis in the
iagnostic hierarchical block in Table 1 with the lowest
umerical value was retained, prioritizing diagnoses by
ardiovascular specialists. We adhered to the guiding prin-
iple of minimizing, to the greatest extent possible, subjec-
ive opinion in categorizing lesions. Thus, each diagnostic
ategory encompasses a spectrum of severity, with no
udgment as to physiologic or clinical ramifications. Lesions
ncluded in block 1 of Table 1 were considered “severe,”
ecause these diagnoses were most likely to be associated
ith cyanosis or require surgical intervention in early life
1). To minimize misclassification errors, this systematic
lgorithmic approach was subject to sensitivity analyses of
andomly selected samples within each diagnostic category
1,8). All discrepancies were reviewed and adjudicated by 2
ndependent CHD specialists.
tudy design. A retrospective open-cohort study was con-
ucted, with a maximum follow-up of 18 years, by identi-
ying all patients with CHD alive each year from July 1,
Abbreviations
and Acronyms
CHD  congenital heart
disease
CI  confidence interval
ICD-9  International
Classification of Disease-
9th Revision
IQR  interquartile range987, to June 30, 2005. Given that congenital disease is Iresent at birth, patients with any diagnostic code for CHD
etween January 1, 1983, and June 30, 2005, entered the
tudy cohort on July 1, 1987, if alive and born prior to that
ate, or at birth if born after that date.
ortality data. In Quebec, death certificates must contain
ominal and demographic data, along with the individual’s
nique and unvarying Medicare number. By law, the attes-
ation of death must be sent to the registrar of civil status
ho then forwards this information to the Quebec Health
nsurance Board. Further validation of mortality data occurs
y cross-referencing vital status information provided by
ther Quebec institutions. Documentation of death is the-
retically complete in this database, whether it occurs in or
ut of hospital. In addition, the hospital discharge database
as used to cross-reference in-hospital deaths. Since this
atabase was initiated in 1987, the beginning of follow-up
as defined as July 1, 1987, to optimize data accuracy and
llow fiscal years to be compared with general Quebec popu-
ation data. With this strategy, originally developed to maxi-
ize reliability of vital status information for patients without
HD, death could be confirmed in 99.75% of cases (9).
tatistical analysis. In descriptive analyses, the distribution
f age at death among subjects with CHD who died in a
iven fiscal year, starting from July 1, 1987, was character-
zed by histogram plots and medians and interquartile
anges (IQRs) (25th, 75th percentiles). Median ages at
eath in selected years were compared with Kruskal-Wallis
ests.
ierarchical Classificationf Congenital Heart DiseaseTable 1 Hier rchical Classificationof Congenital Heart Disease
Block Diagnostic Codes ICD-9 Code
1 Endocardial cushion defect 745.6
Tetralogy of Fallot 745.2
Univentricular heart 745.3
Transposition complex 745.1
Truncus arteriosus 745.0
Hypoplastic left heart syndrome 746.7
2 Atrial septal effect 745.5
Ventricular septal defect 745.4
Patent ductus arteriosus 747.0
Aortic coarctation 747.1
Ebstein’s anomaly 746.2
3 Unspecified defect of septal closure 745.9
4 Anomalies of the pulmonary artery 747.3
Anomalies of the pulmonary valve 746.0
Congenital tricuspid valve disease 746.1
Congenital aortic stenosis 746.3
Congenital aortic insufficiency 746.4
Congenital mitral stenosis 746.5
Congenital mitral insufficiency 746.6
Anomalies of great veins 747.4
5 Other unspecified anomalies of the heart 746.8/9
Other unspecified anomalies of the circulation 747.9
Other unspecified anomalies of the aorta 747.2CD-9  International Classification of Disease-9th Revision.
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September 28, 2010:1149–57 Changing Mortality in Congenital Heart DiseaseStatistical analyses focused on changes in mortality rates
cross six 3-year time intervals, from 1987 to 1990, to 2002
o 2005. These analyses accounted for the fact that some
ubjects were identified only at time of death and, thus,
imilar subjects who did not die in the same period were not
dentified, or were identified only much later in the data-
ase. To avoid resulting biases in estimating mortality rates,
tatistical analyses were, therefore, limited to restricted
ohorts. Restricted cohorts were defined as the population
f subjects indentified prior to the beginning of each 3-year
nterval who remained alive (i.e., “at risk”) at the beginning
f the interval. For every subject in a given restricted cohort,
eath within the corresponding 3-year period was modeled
s a binary dependent variable. Adjusted mortality rates in
he periods 1990 to 1993, to 2002 to 2005 were compared
ith the earliest period (1987 to 1990) with multivariate
oisson regression models that controlled for age at the
eginning of the period, sex, and subtype of CHD catego-
ized as severe, simple shunt, and other. Since individual
atients may have been included in more than 1 restricted
ohort, analyses were performed with and without the
eneralized estimating equations (GEE) extension of Pois-
on regression (10) to account for the dependence of
ithin-subject observations (11). Since the 2 approaches
ielded similar results, we report adjusted mortality rate
atios and their 95% confidence intervals (CIs) without
EE. Poisson regression analyses of all CHD lesions
ere performed separately for 6 age groups. For each age
roup, adjusted mortality rate ratios were likewise estimated
rom general Quebec population data using Poisson regres-
ion adjusted for sex and age within each group (except
nfants). In lesion-specific analyses, to ensure sufficient
tatistical power, patients were regrouped as children (age
18 years) or adults (age 18 to 65 years), and less frequent
HD subtypes were not considered.
Two-tailed p values 0.05 were considered statistically
ignificant. All analyses were performed using SAS software
ersion 9.1 (SAS Institute, Cary, North Carolina).
esults
tudy population. The full cohort was comprised of
1,686 patients with CHD followed for 982,363 patient-
ears. The general Quebec population varied between 6.8
nd 7.5 million people during the first (1987 to 1988) and
nal (2004 to 2005) years of follow-up, respectively. Char-
cteristics of the full and restricted cohorts are summarized
n Table 2.
istribution of age at death in CHD. A total of 8,561
11.9%) deaths occurred during follow-up. As portrayed by
he histogram on the left of Figure 1, the distribution of age
t death during the first year of observation (1987 to 1988)
isplayed a bimodal pattern, with the highest mortality peak pn infancy and a lower peak in later adulthood. In contrast,
y the last year (2004 to 2005), the distribution shifted
oward deaths at older ages, becoming nearly unimodal
right-hand graph in Fig. 1). In 1987 to 1988, 49.0% of
eaths in patients with CHD occurred under the age of 20,
hereas by 2004 to 2005, only 9.3% of deaths occurred
nder age 20 years. Although in 2004 to 2005, deaths at
ges 0 to 4 years remained somewhat more frequent than in
ater childhood, the distribution of age at death after 4 years
f age approximated that of the general Quebec population
bold curve).
emporal changes in mortality. Overall, the median age
t death increased by 15 years, from 60 years (IQR: 3 to 76
ears) in 1987 to 1993, to 75 years (IQR: 60 to 83 years) in
999 to 2005 (p  0.001). In patients with severe forms of
HD, the median age at death increased from 2 years
IQR: 1 to 13 years) in 1987 to 1993, to 23 years (IQR: 1
o 56 years) in 1999 to 2005 (p  0.001). Table 3
ummarizes the number of deaths in each restricted cohort
nd the proportion of deaths that occurred in patients with
evere versus other forms of CHD, and in children versus
dults.
Figure 2 shows how adjusted mortality rates varied over
ime for each age category, relative to the first 3 years of
bservation. The mortality reduction in children with CHD
as greatest in infants, became smaller with increasing age,
nd exceeded that of the general population. Infants with
HD experienced a 77% reduction in mortality (mortality
ate ratio: 0.23, 95% CI: 0.12 to 0.47, p  0.001), in
omparison to a 52% decline (mortality rate ratio: 0.48, 95%
I: 0.38 to 0.60, p  0.001) in the general infant popula-
ion. For children 5 to 17 years of age, the mortality
eduction was 66% (mortality rate ratio: 0.34, 95% CI: 0.21
o 0.54, p 0.001) in the CHD cohort compared with 50%
mortality rate ratio: 0.50, 95% CI: 0.45 to 0.55, p  0.001)
n the general population.
In all but the oldest age group, adults with CHD
xperienced statistically significant reductions in mortality
hat paralleled general population trends. Mortality rate
atios for adults 18 to 34 years of age with CHD and in the
eneral population were 0.60 (95% CI: 0.40 to 0.90, p 
.02) and 0.64 (95% CI: 0.61 to 0.67, p  0.001),
espectively. For adults 35 to 64 years of age, corresponding
ortality rate ratios were 0.72 (95% CI: 0.55 to 0.93, p 
.02) and 0.70 (95% CI: 0.69 to 0.71, p 0.001). Mortality
ates declined in the general population of adults age 65
ears (mortality rate ratio: 0.78, 95% CI: 0.77 to 0.78, p 
.001), but not in the CHD cohort (Fig. 2).
Table 4 provides adjusted mortality rate ratios, according
o CHD subtype, separately for all patients, children, and
dults 18 to 64 years old. Gains in survival were mostly
riven by decreased mortality in severe forms of CHD,
articularly in children who experienced a 67% reduction in
ortality (mortality rate ratio: 0.33, 95% CI: 0.19 to 0.60,
 0.001).
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eart defects are the most common form of congenital
isease, with an estimated prevalence of 11.9 per 1,000
hildren in 2000 (1). Three decades ago, CHD was consid-
red a predominantly pediatric condition, as patients with
omplex forms seldom survived beyond childhood. How-
ver, patient care markedly improved, resulting in a growing
nd aging population. Indeed, adults now outnumber chil-
ren with both severe and other types of CHD (1).
One may expect that these observed population trends
hould be reflected in changing mortality patterns. How-
ver, estimation of population-based mortality in CHD is
hallenging. Prior studies have largely been restricted to
esion-specific retrospective cohort studies or surgical series,
ith a few population-based analyses based on birth defects
r death registries (5,12–16). Birth registry studies are
imited to subjects diagnosed within the first year of life
17,18). Milder forms of CHD may escape detection until
ater years, thereby potentially skewing such results towards
ore severe subtypes. In contrast, mortality studies relying
n death registries have focused on subjects in whom CHD
Characteristics of the Full and Restricted Cohorof Patients With Congenital Heart DiseaseTable 2 Charact ristics of the Full nd Restof Patients With Congenital Heart D
Deaths, n (%)
Age category on July 1, 1987, yrs
1
1–4
5–17
18–34
35–64
65
Born after July 1, 1987
Sex
Females
Males
Missing†
Congenital heart disease diagnosis
Severe congenital heart disease
Endocardial cushion defect
Tetralogy of Fallot
Transposition of the great arteries
Univentricular heart‡
Truncus arteriosus
Other forms of congenital heart disease
Atrial septal defect
Ventricular septal defect
Patent ductus arteriosus
Aortic coarctation
Ebstein’s anomaly
Other
Values are presented as n (%). *Six restricted cohorts were created
identifying congenital heart disease subjects who were alive and, the
cohorts were used for the analyses of mortality rates (see Statistical A
by a temporary administrative database prior to allocation of the permas considered the main cause of demise (13,19). Yet, in alder patients with CHD, sudden (14,20) and heart failure–
elated (5,21) deaths are common. Restricting deaths to
hose attributed to CHD may exclude most fatalities,
articularly among adults, thereby biasing the resulting
istribution of age at death towards younger years (13).
The comprehensiveness of administrative databases in
uebec provided us with a unique opportunity to assemble
population-based cohort with CHD that was not re-
tricted to those diagnosed in infancy. “All cause mortality,”
hich encompasses deaths that may or may not have been
elated to CHD, was deliberately selected as the primary
utcome, given its indisputable clinical relevance, previously
alidated high degree of accuracy (9), and applicability to
eneral population data for comparative purposes. Our
ystematic algorithmic approach, with sensitivity analyses of
andomly selected samples, was developed to minimize
iagnostic misclassification errors (1,8), whereas our multi-
ariate analyses of restricted cohorts were designed to
inimize selection bias and confounding by type of CHD.
sing this methodology, we found that age at death
ncreased over time. Adjusted mortality rates declined in all
d Cohorts
se
Full Cohort
(n  71,686)
Restricted Cohort*
(n  57,663)
8,561 (11.9) 5,967 (10.3)
1,154 (1.6) 1,054 (1.8)
4,451 (6.2) 4,238 (7.3)
10,129 (14.1) 9,092 (15.8)
9,320 (13.0) 8,168 (14.2)
14,944 (20.8) 11,999 (20.8)
4,881 (6.8) 3,897 (6.8)
26,807 (37.4) 19,215 (33.3)
38,031 (53.0) 30,824 (53.5)
32,563 (45.4) 26,232 (45.5)
1,092 (1.5) 607 (1.0)
2,204 (3.1) 1,946 (3.4)
2,084 (2.9) 1,804 (3.1)
1,011 (1.4) 810 (1.4)
669 (0.9) 499 (0.9)
301 (0.4) 236 (0.4)
17,186 (24.0) 13,194 (22.9)
14,550 (20.3) 12,315 (21.4)
2,070 (2.9) 1,527 (2.6)
1,385 (1.9) 1,131 (2.0)
191 (0.3) 143 (0.2)
30,005 (41.9) 24,058 (41.7)
h of the 3-year intervals from 1987 to 1990, to 2002 to 2005 by
“at risk” at the beginning of the respective 3-year period. Restricted
section). †Sex was not available for infant deaths that were captured
unique identifier. ‡Includes hypoplastic left heart syndrome.tsricte
isea
for eac
refore,ge categories under 65 years. From 1987 to 1990, to 2002
t
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September 28, 2010:1149–57 Changing Mortality in Congenital Heart Diseaseo 2005, mortality decreased by 59% in children, exceeding
eneral population trends, and by 16% in adults 18 to 64
ears of age, matching the general population. Children
ith severe forms of CHD experienced a 67% reduction in
ortality, with a consistent effect across most subtypes.
lthough comparable U.S. data are not available, these
bservations are consistent with a report from the federal
nteragency forum on child and family statistics, which
aptures representative data on large segments of the pop-
lation (22). During a similar period of observation, death
ates from birth defects and heart disease declined by 50%
nd nearly 60%, respectively (22).
Figure 1 Distribution of Age at Death in Patients With Congeni
Histogram bars depict the proportion of all deaths (x-axis) according to age at dea
1988; left) and final (2004 to 2005; right) years of observation. Bold black curve
Quebec population during the same periods of observation.
eaths in the 6 Restricted Cohorts of Patients With CHDTable 3 Deaths in the 6 Restricted Cohorts of Patients With C
1987–1990 1990–1
Total population with CHD
Number of deaths 303 5
Number of patients 13,772 22,6
Severe vs. other forms of CHD
Number of deaths in severe CHD 61 (20) 78 (
Number of patients with severe CHD 2,387 2,9
Number of deaths in other forms of CHD 242 (80) 513 (
Number of patients with other forms of CHD 11,385 19,6
Children vs. adults with CHD
Number of deaths in children with CHD 89 (29) 78 (
Number of children with CHD* 7,568 10,9
Number of deaths in adults with CHD 214 (71) 513 (
Number of adults with CHD* 6,204 11,7alues are n or n (%). *Age is measured at the beginning of each time period (e.g., on July 1, 1987, for t
CHD  congenital heart disease.Changing mortality in CHD is likely multifactorial,
eflecting major strides in patient care and improvements in
urvival in the population as a whole. Changing mortality
ates in CHD must, therefore, be interpreted within the
ontext of general population data. A rapid decline in fetal
nd infant mortality rates in the general population of
ndustrialized nations has been previously reported. Indeed,
nfant mortality is considered one of the most important
ndicators of the health of a nation, and has been associated
ith a variety of factors such as maternal health, quality and
ccess to medical care, socioeconomic conditions, and public
ealth practices (23). Factors specific to the decline in infant
eart Disease in 1987 to 1988 and 2004 to 2005
xis) in our cohort of patients with congenital heart disease in the first (1987 to
diamonds represent the corresponding age at death distribution in the general
1993–1996 1996–1999 1999–2002 2002–2005
927 1,176 1,425 1,545
30,886 38,372 45,747 53,241
77 (8) 105 (9) 89 (6) 84 (5)
3,426 3,958 4,410 4,887
850 (82) 1,071 (91) 1,336 (94) 1,461 (95)
27,460 34,414 41,337 48,354
95 (10) 78 (7) 79 (5) 62 (4)
14,087 16,392 19,566 22,228
832 (90) 1,098 (93) 1,346 (95) 1,483 (96)
16,799 21,980 26,181 31,013tal H
th (y-a
s withHD
993
91
52
13)
94
87)
58
13)
43
87)
09he first restricted cohort).
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Changing Mortality in Congenital Heart Disease September 28, 2010:1149–57ortality in patients with CHD may include the impact of
renatal diagnosis and early detection (24); novel surgical
rocedures such as the arterial switch operation for trans-
osition of the great arteries (25) and Norwood variants for
ingle ventricles (26); interventional procedures such as
alloon angioplasty for critical aortic stenosis and pulmo-
ary stenosis (27); organization of care into intensive care
nits with coordinated efforts of specialized team members
28); and miniaturization of tools and techniques (29). In
Figure 2 Adjusted Age-Specific Changes in Mortality Over Time
For each of the 6 age categories (6 panels), adjusted mortality rate ratios (black s
ence cohort (1987 to 1990). Mortality rates are based on restricted cohorts (see
controlled for residual age differences, sex, and type of congenital heart disease.
tive database prior to allocation of the permanent unique identifier. The difference
vertical bar for the 95% confidence interval does not cross the horizontal dotted lddition, a disproportionate termination of fetuses with the oost severe forms of CHD may contribute to a less severe
ase-mix (30) that cannot be fully adjusted for in analyses.
Factors contributing to decreased mortality in older
hildren and adolescents with CHD may include earlier
etection, improvements in diagnostic techniques, refine-
ent of selection criteria and risk assessment for surgical or
ercutaneous interventions, advances in surgical and peri-
perative care, and progress in outpatient management and
ollow-up (31,32). Importantly, the reduction in mortality
hildren and Adults With Congenital Heart Disease
s) and 95% confidence intervals (vertical lines) are plotted relative to the refer-
ical Analysis section) and were estimated by Poisson regression models that
as not available for infant deaths that were captured by a temporary administra-
rtality is statistically significant at a 2-tailed alpha of 0.05, if the corresponding
rresponding to a mortality rate ratio of 1).in C
quare
Statist
Sex w
in mo
ine (cobserved in children was not accompanied by an increased
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September 28, 2010:1149–57 Changing Mortality in Congenital Heart Diseaseortality rate in adults. In adults 18 to 64 years of age, the
ortality rate declined by a comparable amount to the
eneral population, suggesting that adults with CHD ben-
fited from overall gains in population health. For reasons
hat remain speculative, mortality rates did not decrease in
he oldest subgroup (age 65 years) with CHD, unlike the
eneral population. Older age and comorbid conditions,
uch as chronic renal disease, heart failure, myocardial
nfarction, and malignant cancer, have been associated with
ortality in adults with CHD65 years of age (33). It may
e hypothesized, therefore, that even within a given diag-
ostic category, patients who survived beyond 65 years in
he earlier period had less severe disease and/or comorbid
onditions when compared with “survivors” from later years.
f so, for this age group, an improvement in population
ealth may have been offset by residual confounding due to
“healthy survivor” effect.
Implications of decreasing mortality in CHD are consid-
rable, particularly with regards to allocation of appropriate
esources. It was once true that older patients had predom-
nantly simple lesions compared with children. However,
he absolute number of adults with CHD is now steadily
ncreasing (1), with a spectrum of disease that is transition-
ng towards more complex forms, as even patients with
evere subtypes survive beyond childhood. Neurocognitive
mpairment, which may range from subtle to overt, is well
ecognized in children with severe forms of CHD (34). Its
mpact on the aging and increasingly complex population
ith CHD is likely to be substantial, with implications for
ducation, employability, insurability in the U.S., and more
obust neurocognitive assessment and intervention. In ad-
ition, complications such as arrhythmias and heart failure
ften appear in later life (35), and health care needs and
osts are generally highest in the year preceding death (36).
The burden of health in CHD is, therefore, shifting
oward the adult. Further studies are required to determine
he impact of changing mortality in CHD on a global scale.
djusted Mortality Rate Ratios in Subtypes of Congenital Heart DisTable 4 Adjusted Mortality Rate Ratios in Subtypes of Congen
Type of Congenital Heart Disease
All Patients
Adjusted Mortality Ratio*
(95% CI) p Value
All types of congenital heart disease 0.69 (0.61–0.79) 0.001
Severe congenital heart disease 0.51 (0.37–0.72) 0.001
Endocardial cushion defect 0.52 (0.26–1.02) 0.06
Tetralogy of Fallot 0.54 (0.31–0.95) 0.03
Transposition of the great arteries 0.39 (0.17–0.89) 0.03
Univentricular hearts† 0.52 (0.22–1.25) 0.15
Other forms of congenital heart disease
Atrial septal defect 0.79 (0.57–1.11) 0.17
Ventricular septal defect 0.40 (0.28–0.59) 0.001
Patent ductus arteriosus 0.90 (0.37–2.20) 0.82
Adjusted mortality rate ratios and 95% confidence intervals (CIs) for the final (2002 to 2005) relati
nalysis section) with Poisson regression that controlled for age, sex, and type of congenital hear
NE  nonestimable due to the limited number of deaths.hereas provision of care for children with CHD is well istablished in developed countries, clinical services for
dults are comparatively scarce (37,38). Our findings lend
urther support to the urgent call for additional resources for
ducation, training, research, and patient care in adults with
HD (39).
tudy limitations. The targeted catchment population was
he entire province of Quebec. However, subjects with
HD who had no contact with the health care system from
anuary 1983 to June 2005 were not captured. This is more
ikely to affect those with mild forms of disease. Addition-
lly, the open cohort design carries a higher risk for missing
ubjects with a shorter time frame to establish a diagnosis of
HD, either because they were born closer to the end of the
tudy period or died shortly after the cohort inception.
owever, this potential bias should not have a sizeable
mpact on observed changes in ages at death since median
alues are quite robust with respect to the potential omission
f a relatively small fraction of the total population. To
void potential biases, our primary analyses of mortality
ates were limited to restricted cohorts of subjects “at risk” at
he beginning of each observation period (i.e., employed the
ame criteria to identify the population in the “denomina-
or” and deaths in the “numerator”). Furthermore, since
election bias may result from a higher likelihood of detect-
ng milder forms of CHD in more recent calendar years, we
djusted for CHD subtype. In addition, the proportion of
atients who died, but were not included in restricted
ohorts, were compared in an exploratory analysis. Since the
roportion of excluded deaths stayed relatively constant over
ime, one could reasonably conclude that the selection effect
ad not changed substantially over time. To further address
he potential for left-censoring bias, we conducted an
nalysis that restricted inclusion to patients diagnosed with
HD within 4 years of the start of each successive cohort.
espite the exclusion of 42% of deaths, this sensitivity
nalysis yielded congruent results (e.g., overall adjusted
ortality rate ratio 0.69 [95% CI: 0.62 to 0.77] in compar-
in 2002 to 2005 Relative to 1987 to 1990eart Disease in 2002 to 2005 Relative to 1987 to 1990
Children (Age <18 yrs) Adults (Age 18–64 yrs)
justed Mortality Ratio*
(95% CI) p Value
Adjusted Mortality Ratio*
(95% CI) p Value
0.41 (0.29–0.56) 0.001 0.84 (0.73–0.97) 0.02
0.33 (0.19–0.60) 0.001 0.67 (0.39–1.14) 0.14
0.37 (0.12–1.15) 0.09 1.02 (0.23–4.48) 0.98
0.45 (0.19–1.07) 0.07 0.58 (0.26–1.32) 0.20
0.14 (0.03–0.67) 0.01 0.88 (0.19–4.03) 0.87
0.21 (0.04–1.02) 0.05 0.75 (0.17–3.38) 0.71
1.14 (0.34–3.84) 0.84 0.77 (0.54–1.09) 0.14
0.28 (0.13–0.60) 0.001 0.54 (0.34–0.87) 0.01
NE 1.36 (0.47–3.94) 0.57
e first (1987 to 1990) period of observation were estimated from restricted cohorts (see Statistical
e. †Includes hypoplastic left heart syndrome.easeital H
Ad
ve to thson to 0.69 [95% CI: 0.61, 0.79]).
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Changing Mortality in Congenital Heart Disease September 28, 2010:1149–57Our diagnostic classification system was limited by the
CD-9 codes. This coding system was previously used to
uantify prevalence rates, births, and deaths in CHD
1,13,40). Given our reliance on administrative databases,
iagnostic misclassification errors remain possible despite
very effort to maximize data accuracy. However, misclas-
ification errors are likely nondifferential such that any
esulting potential bias would be towards the null (41) and
ould not, therefore, explain the observed statistically sig-
ificant decreases in mortality. Finally, the impact of socio-
conomic status was not assessed in the current analysis, and
thnic origin is not available in our concatenation of data
esources. Nevertheless, racial variation, as reflected by the
roportion of visible minorities in census bureau statistics, is
ubstantially less in Quebec compared with the U.S.
opulation.
onclusions
n this large population-based study, we report a marked
eduction over time in infant mortality, an increase in age
t death, and decreasing mortality rates in children and
dolescents with CHD. A consistent pattern is, therefore,
merging with regards to changing population trends.
ith decreasing mortality in the young, the CHD
opulation is growing and aging (1). These changes are
ost notable for young patients with severe defects and
xceed general population trends. The burden of health
s, therefore, transitioning away from the child and
owards the adult with CHD. The health community is
hallenged to meet these secular trends with appropriate
llocation of resources.
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